First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of ...

Researchers from the USC Norris Comprehensive Cancer Center and collaborators report that they have found evidence that targeting CD47, a protein that is part of the innate immune system, could be a ...

CD47-directed therapies offer a novel immuno-oncology strategy for engaging the innate immune system in a variety of tumor types. Early results provide a rationale for expanding trials with promising ...

Dublin, Oct. 01, 2025 (GLOBE NEWSWIRE) -- The "CD47 Inhibitors Drug Market Opportunity, Clinical Application by Indications & Clinical Trials Insight 2026" report has been added to ...

Traditionally, cancer management has primarily relied on surgery, radiation therapy, and chemotherapy. While these treatments have demonstrated significant efficacy in eradicating primary tumors, they ...

Phagocytosis relies on a balance between prophagocytic (“eat me”) and antiphagocytic (“don't eat me”) signals on target cells 1,2,3. CD47, initially observed on stem cells, is a transmembrane protein ...

Gilead Sciences has said it will no longer develop its CD47-targeting antibody magrolimab in blood cancers after data suggested that patients taking the drug in clinical trials were more likely to die ...

Bone fracture healing is a highly coordinated process involving inflammation, fibrovascular formation, and mineralization. Vascularization plays a pivotal role, as inadequate blood supply can severely ...

Gilead Sciences' CD47 cancer program is back on track—for the most part—after the FDA lifted clinical holds placed in January on five trials. But the agency is keeping two additional trials on ice, ...